Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2022; 28(25): 2843-2853
Published online Jul 7, 2022. doi: 10.3748/wjg.v28.i25.2843
Characteristics of inflammatory bowel diseases in patients with concurrent immune-mediated inflammatory diseases
Shintaro Akiyama, Soma Fukuda, Joshua M Steinberg, Hideo Suzuki, Kiichiro Tsuchiya
Shintaro Akiyama, Soma Fukuda, Hideo Suzuki, Kiichiro Tsuchiya, Department of Gastroenterology, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan
Joshua M Steinberg, Inflammatory Bowel Disease, Gastroenterology of the Rockies, Denver, CO 80218, United States
Author contributions: Akiyama S designed the research; Akiyama S and Fukuda S performed the research and analyzed the data; Akiyama S, Fukuda S, Steinberg JM, Suzuki H, and Tsuchiya K wrote the paper.
Conflict-of-interest statement: Akiyama S, Fukuda S, and Suzuki H have no relevant disclosures; Steinberg JM was on Advisory Board for Pfizer; Tsuchiya K has received grant supports from Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharmaceutical Corp., and Hitachi Ltd.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shintaro Akiyama, MD, MSc, PhD, Lecturer, Department of Gastroenterology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Ibaraki, Japan. akiyama@md.tsukuba.ac.jp
Received: January 8, 2022
Peer-review started: January 8, 2022
First decision: March 9, 2022
Revised: March 10, 2022
Accepted: May 28, 2022
Article in press: May 28, 2022
Published online: July 7, 2022
Core Tip

Core Tip: Patients with inflammatory bowel disease (IBD) are more likely to acquire other immune-mediated inflammatory diseases (IMIDs). IBD patients with concurrent IMIDs were more likely to require biologics and IBD-related surgeries than non-IBD patients due to extensive disease phenotypes according to recent studies. As a result, when treating IBD patients, we must be aware of the concurrence of other IMIDs and understand its pathogenesis to select biologic and small molecule therapies that treat multiple concomitant diseases.